MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Ionis Pharmaceuticals Inc

Open

SectorHealthcare

27.96 -0.6

Overview

Share price change

24h

Current

Min

27.7

Max

28.73

Key metrics

By Trading Economics

Income

36M

-104M

Sales

93M

227M

P/E

Sector Avg

539.57

63.778

EPS

-0.43

Profit margin

-46.055

Employees

1,069

EBITDA

44M

-81M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+106.24% upside

Dividends

By Dow Jones

Next Earnings

6 May 2025

Market Stats

By TradingEconomics

Market Cap

258M

5B

Previous open

28.56

Previous close

27.96

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ionis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Sept 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 Sept 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Peer Comparison

Price change

Ionis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

106.24% upside

12 Months Forecast

Average 56.22 USD  106.24%

High 78 USD

Low 38 USD

Based on 19 Wall Street analysts offering 12 month price targets forIonis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

11

Buy

8

Hold

0

Sell

Technical Score

By Trading Central

N/A / 32.94Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.